Alterity Therapeutics Net Worth
Alterity Therapeutics Net Worth Breakdown | ATHE |
Alterity Therapeutics Net Worth Analysis
Alterity Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Alterity Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Alterity Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Alterity Therapeutics' net worth analysis. One common approach is to calculate Alterity Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Alterity Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Alterity Therapeutics' net worth. This approach calculates the present value of Alterity Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Alterity Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Alterity Therapeutics' net worth. This involves comparing Alterity Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Alterity Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Alterity Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Alterity Therapeutics' net worth research are outlined below:
| Alterity Therapeutics generated a negative expected return over the last 90 days | |
| Alterity Therapeutics has some characteristics of a very speculative penny stock | |
| Alterity Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 4.02 M. Net Loss for the year was (19.12 M) with profit before overhead, payroll, taxes, and interest of 3.63 M. | |
| Alterity Therapeutics currently holds about 34.81 M in cash with (12.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.87. | |
| Alterity Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Alterity Therapeutics reports annual general meeting results |
Know Alterity Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Alterity Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Alterity Therapeutics backward and forwards among themselves. Alterity Therapeutics' institutional investor refers to the entity that pools money to purchase Alterity Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Coppell Advisory Solutions Llc | 2024-06-30 | 5.0 | Ubs Group Ag | 2024-06-30 | 2.0 | Xtx Topco Ltd | 2024-06-30 | 0.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 96.8 K | Hb Wealth Management, Llc | 2024-09-30 | 23.8 K | Susquehanna International Group, Llp | 2024-06-30 | 23.3 K | Citadel Advisors Llc | 2024-09-30 | 11.5 K | Twin Lakes Capital Management, Llc | 2024-06-30 | 5.9 K | Providence Capital Advisors, Llc | 2024-06-30 | 200 | Advisor Group Holdings, Inc. | 2024-06-30 | 81.0 | Ronald Blue Trust, Inc. | 2024-09-30 | 40.0 |
Follow Alterity Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.24 M.Market Cap |
|
Project Alterity Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.99) | (1.04) | |
| Return On Capital Employed | (1.42) | (1.49) | |
| Return On Assets | (0.99) | (1.04) | |
| Return On Equity | (1.39) | (1.32) |
When accessing Alterity Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Alterity Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Alterity Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Alterity Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Alterity Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Alterity Therapeutics' management manipulating its earnings.
Evaluate Alterity Therapeutics' management efficiency
Alterity Therapeutics has return on total asset (ROA) of (0.5266) % which means that it has lost $0.5266 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0447) %, meaning that it created substantial loss on money invested by shareholders. Alterity Therapeutics' management efficiency ratios could be used to measure how well Alterity Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 27, 2024, Return On Tangible Assets is expected to decline to -1.04. In addition to that, Return On Capital Employed is expected to decline to -1.49. At present, Alterity Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 22.58, whereas Non Current Assets Total are forecasted to decline to about 177.5 K.| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (0.29) | (0.31) | |
| Price Book Value Ratio | 1.32 | 1.39 | |
| Enterprise Value Multiple | (0.29) | (0.31) | |
| Price Fair Value | 1.32 | 1.39 | |
| Enterprise Value | 5.8 M | 5.5 M |
Examining the leadership quality of Alterity Therapeutics offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.
Enterprise Value Revenue 113.9898 | Revenue 4 M | Quarterly Revenue Growth 0.384 | Revenue Per Share 0.6 | Return On Equity (1.04) |
Alterity Therapeutics Earnings per Share Projection vs Actual
Alterity Therapeutics Corporate Management
| Robert Cherny | Head Research | Profile | |
| BBus CA | Company Sec | Profile | |
| BSc BSc | CoFounder Chairman | Profile | |
| Kathryn Andrews | Chief Officer | Profile | |
| Steven Targum | Chief Advisor | Profile | |
| CPA BCom | Chief Officer | Profile | |
| Steven MD | Chief Advisor | Profile |
Already Invested in Alterity Therapeutics?
The danger of trading Alterity Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alterity Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alterity Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alterity Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Alterity Therapeutics is a strong investment it is important to analyze Alterity Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Alterity Therapeutics' future performance. For an informed investment choice regarding Alterity Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alterity Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alterity Therapeutics. If investors know Alterity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alterity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.84) | Revenue Per Share 0.6 | Quarterly Revenue Growth 0.384 | Return On Assets (0.53) | Return On Equity (1.04) |
The market value of Alterity Therapeutics is measured differently than its book value, which is the value of Alterity that is recorded on the company's balance sheet. Investors also form their own opinion of Alterity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alterity Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alterity Therapeutics' market value can be influenced by many factors that don't directly affect Alterity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alterity Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alterity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alterity Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.